# ClinChoice

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/clinchoice

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.fountain-med.com
- Total disclosed funding: $214M
- Latest round: Series E (Jul 5, 2022)
- Investors on record: 11

## About

Founded in 2007 and based in Beijing, China, ClinChoice operates as a contract research organization that provides the International Council for Harmonisation(ICH) Good Clinical Practice(GCP) research services to the pharmaceutical, biotechnology, and medical device industries, with over 1800 clinical research professionals in more than 50 cities and 7 countries around the world. In July 2022, the company raised USD 150 million in series E funding. Ling Zhen is the CEO and chairman of the board of the company, and he was a partner at the Draper Dragon Venture Group.

The company's main business includes clinical operations, project management, biostatistics, data management, statistical programming, regulatory affairs, medical affairs, feasibility studies, human genetic resources' management, clinical safety management, clinical trial site management, natural medicine/Chinese medicine, and clinical phase I services. The company's therapeutic areas include oncology, neurology, metabolism, respiratory, autoimmune, ophthalmology, musculoskeletal, urology, anti-infective, and rare diseases.

The company plans to use the series E funding for the continued expansion of medical services in China and overseas, as well as innovative business development, mergers, and acquisitions.

## Funding rounds

- Series E, Jul 5, 2022, $150M — Legend Capital, Lilly Asia Ventures, Oriza Holdings, Apricot Capital, Taikang Life Insurance, Sherpa Healthcare Partners
- Series D, Oct 25, 2019, $62M — Lilly Asia Ventures, Goldman Sachs Asset Management
- Series C, Mar 1, 2016 — Apricot Capital
- Series B, Mar 1, 2015 — YuanBio Venture
- Series A, Dec 31, 2009, $0.3M — DFJ DragonFund China
- Angel, Jan 1, 2008 — Cowin Capital
- Seed, Dec 31, 2007, $1.2M — Tianjin Venture Capital, DFJ DragonFund China

## Investors

- Tianjin Venture Capital (https://capitalatlas.ai/funds/tianjin-venture-capital) — Seed
- DFJ DragonFund China (https://capitalatlas.ai/funds/dfj-dragonfund-china) — Seed, Series A
- Cowin Capital (https://capitalatlas.ai/funds/cowin-capital) — Angel
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series B
- Apricot Capital (https://capitalatlas.ai/funds/apricot-capital) — Series C, Series E
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series D, Series E
- Goldman Sachs Asset Management (https://capitalatlas.ai/funds/goldman-sachs-asset-management) — Series D
- Legend Capital — Series E
- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series E
- Taikang Life Insurance — Series E
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series E